89Zr-TLX250 PET/CT Clinical Trials

1 actively recruiting trial

Also known as: 89Zirconium-labelled girentuximab, 89Zr-DFO-TFP-GTX, 89Zr-DFO-girentuximab, 89Zr-girentuximab

Pipeline

Phase 3: 1

Top Sponsors

Telix Pharmaceuticals (Innovations) Pty Limited1

Indications

Clear Cell Renal Cell Carcinoma1
Cancer1

Other1 trial

89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.